I don't think approval is priced in the current SP.
On approval, it's not only the profit from paediatric indication that should be priced in for valuation purposes, but the platform.
One approval means everything for a platform biotech.
2024 Here we go again., page-628
-
- There are more pages in this discussion • 261 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.000(0.00%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4580 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 1059 | 2 |
View Market Depth
| Last trade - 09.41am 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable